Tuck,
In PM you asked me about PCOP and Eos deal.
Yes, I did choused PCOP as my 2001 pick, but it was great disappointment so far. I was expecting break-up software business this year, and focus on proprietary drugs and targets. Also, progress with collaborators, especially with Roche on MC-R4 agonist. Very little moved forward.
I do not know much about Eos and what they are doing, but in my view it is not in synergy with what PCOP should do. If they do need help on target identification and characterization, collaboration should be sufficient, not merge (which is expensive for PCOP).
Going forward, can PCOP re-discover itself? Maybe! Mollica is good and experienced guy, but for successful business one need good team works, not single person efforts.
Miljenko |
